NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™

On May 29, NeuroPace, Inc. (NASDAQ:NPCE) said it received U.S. Food and Drug Administration support for ECoG Assistant, the archetypal "AI-driven clinician-enabled feature." It is designed to assistance epilepsy attraction utilizing semipermanent intracranial EEG data.

Built connected 124,450 epileptologist-labeled records, the institution reported that the instrumentality has "ECoGs of Interest." It allows physicians to reappraisal trends and timing patterns crossed months done integrated reports and charts, improving ratio successful information reappraisal and attraction decisions.

Chief Medical Officer Martha Morrell said the diagnostic "represents an important advancement," with faster entree to insights for much informed care.

Image Point Fr/Shutterstock.com

CEO Joel Becker said the support shows however the firm's information vantage is moving toward "practical tools for clinicians."

NeuroPace, Inc. (NASDAQ:NPCE) debuted the exertion astatine the ASSFN Annual Meeting connected May 30. It has submitted its next-generation diligent information level for FDA review, targeting support successful the 2nd 4th of 2026.

NeuroPace, Inc. (NASDAQ:NPCE) creates, produces, and markets implantable devices to dainty epilepsy and neurological illnesses. It offers implantable components specified arsenic the RNS neurostimulator and extent and cortical portion leads.

While we admit the imaginable of NPCE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.